Lucentis Approved for Myopic Choroidal Neovascularization
January 3, 2017 – The U.S. FDA approved a new indication for Lucentis® (ranibizumab injection) 0.5mg, manufactured by Genentech. Lucentis is indicated for the treatment of patients with myopic choroidal neovascularization (mCNV), which is a complication of severe near-sightedness that can lead to blindness. Recommended dosing for mCNV is 0.5mg (0.05mL) by intravitreal (eye) injection once monthly for up to three months. Lucentis is a vascular endothelial growth factor (VEGF) inhibitor that was first approved in 2006 for treating diabetic macular edema (DME). It is also approved to treat wet age-related macular degeneration, macular degeneration due to obstructed retinal veins and DME in patients who have diabetic retinopathy.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.